Breaking Finance News

Fresenius (ETR:FRE) stock price target upped to 78.00EUR, reported earlier today by BNP PARIBAS

Fresenius (ETR:FRE) had its target price increased to 78EUR by BNP PARIBAS in an issued report released 9/17/2016. The new target price indicates a potential upside of 0.13% based on the bussiness’ last closing price.

Showing a price of 69.28EUR, Fresenius (ETR:FRE) traded 0.00% even on the day. With the last stock price up 0.00% relative to the 200-day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. The company has registered a 50-day average of 0.00EUR and 200-day average of 0.00EUR. Trading volume was held steady, with 0 shares of FRE changing hands on par with the typical 0 shares.

See Graphic Below:

Fresenius (ETR:FRE)

With a market capitalization of 0.0 EUR, Fresenius has a price-earnings of 0 with a 52 week low of 0.00EUR and a 52 week high of 0.00EUR.

General Company Details For Fresenius (ETR:FRE)

Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company’s operating segments include Fresenius Medical Care; Fresenius Kabi; Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment provides dialysis care and dialysis products for patients with chronic kidney failure. The Fresenius Kabi segment is engaged in provision of intravenously administered drugs (IV drugs), infusion therapies, and clinical nutrition and outpatient care. The Fresenius Helios segment is a private hospital operator and operates 72 clinics. The Fresenius Vamed segment provides engineering and services for hospitals and other health care facilities internationally.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *